Authors:
Maria L. Hugh, LeAnne D. Johnson, & Clayton Cook
University of Washington affiliated authors are displayed in bold.
Subscription Required for Full Text Access
Published: June 2021
Maria L. Hugh, LeAnne D. Johnson, & Clayton Cook
University of Washington affiliated authors are displayed in bold.
Published: June 2021
Sarah Rae Easter, Kelly C. Gilmore, Jay Schulkin, & Julian N. Robinson
University of Washington affiliated authors are displayed in bold.
Published: June 2021
Jessica E Ma, Marie Haverfield, Karl A Lorenz, David B Bekelman, Cati Brown-Johnson, Natalie Lo, Mary Beth Foglia, Jill S Lowery, Anne M Walling, & Karleen F Giannitrapani
University of Washington affiliated authors are displayed in bold.
Published: June 2021
Julie E. Richards, Gregory E. Simon, Jennifer M. Boggs, Rinad Beidas, Bobbi Jo H. Yarborough, Karen J. Coleman, Stacy A. Sterling, Arne Beck, Jean P. Flores, Cambria Bruschke, Julie Goldstein Grumet, Christine C. Stewart, Michael Schoenbaum, Joslyn Westphal, & Brian K. Ahmedani
University of Washington affiliated authors are displayed in bold.
Published: May 2021
Suicide rates continue to rise across the United States, galvanizing the need for increased suicide prevention and intervention efforts. The Zero Suicide (ZS) model was developed in response to this need and highlights four key clinical functions of high-quality health care for patients at risk of suicide. The goal of this quality improvement study was to understand how six large health care systems operationalized practices to support these functions—identification, engagement, treatment and care transitions.
Using a key informant interview guide and data collection template, researchers who were embedded in each health care system cataloged and summarized current and future practices supporting ZS, including, (1) the function addressed; (2) a description of practice intent and mechanism of intervention; (3) the target patient population and service setting; (4) when/how the practice was (or will be) implemented; and (5) whether/how the practice was documented and/or measured. Normalization process theory (NPT), an implementation evaluation framework, was applied to help understand how ZS had been operationalized in routine clinical practices and, specifically, what ZS practices were described by key informants (coherence), the current state of norms/conventions supporting these practices (cognitive participation), how health care teams performed these practices (collective action), and whether/how practices were measured when they occurred (reflexive monitoring).
The most well-defined and consistently measured ZS practices (current and future) focused on the identification of patients at high risk of suicide. Stakeholders also described numerous engagement and treatment practices, and some practices intended to support care transitions. However, few engagement and transition practices were systematically measured, and few treatment practices were designed specifically for patients at risk of suicide.
The findings from this study will support large-scale evaluation of the effectiveness of ZS implementation and inform recommendations for implementation of high-quality suicide-related care in health care systems nationwide.
Many individuals see a health care provider prior to death by suicide, therefore health care organizations have an important role to play in suicide prevention. The Zero Suicide model is designed to address four key functions of high-quality care for patients at risk of suicide: (1) identification of suicide risk via routine screening/assessment practices, (2) engagement of patients at risk in care, (3) effective treatment, and (4) care transition support, particularly after hospitalizations for suicide attempts. Researchers embedded in six large health care systems, together caring for nearly 11.5 million patients, are evaluating the effectiveness of the Zero Suicide model for suicide prevention. This evaluation focused on understanding how these systems had implemented clinical practices supporting Zero Suicide. Researchers collected qualitative data from providers, administrators, and support staff in each system who were responsible for implementation of practices supporting Zero Suicide. Normalization process theory, an implementation evaluation framework, was applied following data collection to: (A) help researchers catalog all Zero Suicide practices described, (B) describe the norms/conventions supporting these practices, (C) describe how health care teams were performing these practices, and (D) describe how practices were being measured. The findings from this evaluation will be vital for measuring the effectiveness of different Zero Suicide practices. This work will also provide a blueprint to help health care leaders, providers, and other stakeholders “normalize” new and existing suicide prevention practices in their own organizations.
**This abstract is posted with permission under the Creative Commons Attribution 4.0 International License**
Emily M. Godfrey, Anna E. Fiastro, Elizabeth A. Jacob-Files, Francine M. Coeytaux, Elisa S. Wells, Molly R. Ruben, Sajal S. Sanan, & Ian M. Bennett
University of Washington affiliated authors are displayed in bold.
Published: April 2021
Yih-Ing Hser, Allison J. Ober, Alex R. Dopp, Chunqing Lin, Katie P. Osterhage, Sarah E. Clingan, Larissa J. Mooney, Megan E. Curtis, Lisa A. Marsch, Bethany McLeman, Emily Hichborn, Laurie S. Lester, Laura-Mae Baldwin, Yanping Liu, Petra Jacobs, & Andrew J. Saxon
University of Washington affiliated authors are displayed in bold.
Published: April 2021
Telemedicine (TM) enabled by digital health technologies to provide medical services has been considered a key solution to increasing health care access in rural communities. With the immediate need for remote care due to the COVID-19 pandemic, many health care systems have rapidly incorporated digital technologies to support the delivery of remote care options, including medication treatment for individuals with opioid use disorder (OUD). In responding to the opioid crisis and the COVID-19 pandemic, public health officials and scientific communities strongly support and advocate for greater use of TM-based medication treatment for opioid use disorder (MOUD) to improve access to care and have suggested that broad use of TM during the pandemic should be sustained.
Nevertheless, research on the implementation and effectiveness of TM-based MOUD has been limited. To address this knowledge gap, the National Drug Abuse Treatment Clinical Trials Network (CTN) funded (via the NIH HEAL Initiative) a study on Rural Expansion of Medication Treatment for Opioid Use Disorder (Rural MOUD; CTN-0102) to investigate the implementation and effectiveness of adding TM-based MOUD to rural primary care for expanding access to MOUD. In preparation for this large-scale, randomized controlled trial incorporating TM in rural primary care, a feasibility study is being conducted to develop and pilot test implementation procedures.
In this commentary, we share some of our experiences, which include several challenges, during the initial two-month period of the feasibility study phase. While these challenges could be due, at least in part, to adjusting to the COVID-19 pandemic and new workflows to accommodate the study, they are notable and could have a substantial impact on the larger, planned pragmatic trial and on TM-based MOUD more broadly. Challenges include low rates of identification of risk for OUD from screening, low rates of referral to TM, digital device and internet access issues, workflow and capacity barriers, and insurance coverage. These challenges also highlight the lack of empirical guidance for best TM practice and quality remote care models.
With TM expanding rapidly, understanding implementation and demonstrating what TM approaches are effective are critical for ensuring the best care for persons with OUD.
**This abstract is posted with permission under the Creative Commons Attribution 4.0 International License**
Stephanie D. Roche, Njeri Wairimu, Peter Mogere, Kevin Kamolloh, Josephine Odoyo, Zachary A. Kwena, Elizabeth A. Bukusi, Kenneth Ngure, Jared M. Baeten, & Katrina F. Ortblad
University of Washington affiliated authors are displayed in bold.
Published: April 2021
As countries scale up pre-exposure prophylaxis (PrEP) for HIV prevention, diverse PrEP delivery models are needed to expand access to populations at HIV risk that are unwilling or unable to access clinic-based PrEP care. To identify factors that may influence implementation of retail pharmacy-based PrEP delivery in Kenya, we conducted in-depth interviews with 40 pharmacy clients, 16 pharmacy providers, 16 PrEP clients, and 10 PrEP providers from two provinces. Most participants expressed strong support for expanding PrEP to retail pharmacies, though conditioned their acceptance on assurances that care would be private, respectful, safe, and affordable. Participant-reported determinants of feasibility centered primarily on ensuring that the intervention is compatible with retail pharmacy operations (e.g., staffing levels, documentation requirements). Future research is needed to develop and test tailored packages of implementation strategies that are most effective at integrating PrEP delivery into routine pharmacy practice in Kenya and other high HIV prevalence settings.
**This abstract is posted with permission under the Creative Commons Attribution 4.0 International License**
John M. Inadomi, Rachel B. Issaka, & Beverly B. Green
University of Washington affiliated authors are displayed in bold.
Published: April 2021
Margaret E. Crane, Katherine E. Phillips, Colleen A. Maxwell, Lesley A. Norris, Lara S. Rifkin, Jacob M. Blank, Samantha D. Sorid, Kendra L. Read, Anna J. Swan, Philip C. Kendall & Hannah E. Frank
University of Washington affiliated authors are displayed in bold.
Published: March 2021
Vivien D. Tsu, D. Scott LaMontagne, Phionah Atuhebwe, Paul N. Bloem, Cathy Ndiaye
University of Washington affiliated authors are displayed in bold.
Published: March 2021
More than 90% of cervical cancer deaths occur in low- and middle-income countries (LMICs), which have limited capacity to mount the comprehensive national screening and precancer treatment programs that could prevent most of these deaths. The development of vaccines against the human papillomavirus (HPV) has dramatically altered the landscape of cervical cancer prevention. As of mid-2020, 56 LMICs (41% of all LMICs) have initiated national HPV vaccination programs. This paper reviews the experience of LMICs that have introduced HPV vaccine into their national programs, key lessons learned, HPV vaccination sustainability and scale-up challenges, and future mitigation measures.
As international guidance evolved and countries accumulated experience, strategies for national introduction shifted with regard to target groups, delivery site and timing, preparation and planning, communications and social mobilization, and ultimately monitoring, supervision and evaluation. Despite the successes that LMICs have been able to achieve in reaching large proportions of eligible girls, there are still considerable challenges countries encounter in overcoming rumors, reaching out-of-school girls, completing the vaccine series, estimating target populations, monitoring program performance, and assuring vaccination sustainability. New opportunities, such as the entry of additional vaccine manufacturers and ongoing studies to evaluate one-dose delivery, could help overcome the outstanding barriers to higher coverage and financial sustainability. Effective use of the experience to date and advances on the horizon could enable all LMICs to move towards the coverage levels that are needed to achieve eventual elimination.
**This abstract is posted with permission under the Creative Commons Attribution 4.0 International License**